Table of Contents Author Guidelines Submit a Manuscript

An erratum for this article has been published. To view the erratum, please click here.

Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 964592, 11 pages
Research Article

NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors

1The Cancer Team at Bellin Health, 1580 Commanche Avenue, Green Bay, WI 54313, USA
2National Center for Complementary and Alternative Medicine, NIH, Bethesda, MD, USA
3Samuelli Institute, Alexandria, VA, USA
4Department of Clinical and Health Psychology, University of Florida, Gainesville, FL, USA
5University of Miami, Miami, FL, USA
6Research Service (151), Veterans Affairs Medical Center, and Department of Medicine, Georgetown University School of Medicine, Washington, DC, USA
7University of Nebraska Medical Center, Omaha, NE, USA
8Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
9Department of Medicine, Hematology and Medical Oncology Division, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

Received 14 April 2013; Revised 23 July 2013; Accepted 17 September 2013

Academic Editor: Gunver Kienle

Copyright © 2013 Patrick J. Mansky et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Patrick J. Mansky, Dawn B. Wallerstedt, Timothy S. Sannes, et al., “NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 964592, 11 pages, 2013.